Summary & Overview
CPT 86052: Aquaporin-4 Antibody Test (Cell-Based Assay)
CPT code 86052 denotes a cell‑based immunofluorescence assay (CBA) to detect antibodies against aquaporin‑4 in serum, a specific biomarker for neuromyelitis optica (NMO). Nationally, testing for AQP4 antibodies is clinically important because it distinguishes NMO from other demyelinating disorders such as multiple sclerosis and guides diagnosis and disease management strategies. The code captures an advanced immunology laboratory service increasingly used in specialty neurology and neuroimmunology care.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of coding and clinical context, payer coverage considerations, common billing modifiers, and relevant operational benchmarks where available. The publication outlines clinical implications of a positive AQP4 antibody result, typical sites of service for performing the assay, and what to expect in terms of laboratory workflow classification under CPT coding standards.
This summary provides a national perspective for clinicians, laboratory managers, and billing professionals seeking clarity on the purpose of CPT code 86052, the clinical scenarios that prompt ordering the test, and the payer landscape addressed in the full publication. Data not available in the input is noted where applicable.
Billing Code Overview
CPT code 86052 describes a laboratory test to detect an antibody to aquaporin‑4 (AQP4), typically performed on a serum specimen. The test uses a cell‑based immunofluorescence assay (CBA) method to identify pathogenic AQP4 antibodies that are a key diagnostic marker for neuromyelitis optica (NMO), an autoimmune disorder affecting the optic nerves, spinal cord, and sometimes brainstem and other central nervous system structures.
Service Type: Immunology / Serologic diagnostic test
Typical Site of Service: Clinical laboratory or hospital outpatient laboratory
Clinical & Coding Specifications
Clinical Context
A 36-year-old woman presents to neurology with subacute bilateral optic neuritis and longitudinally extensive transverse myelitis. Prior evaluation considered multiple sclerosis, but atypical features and severe relapses prompt serologic testing. The neurologist orders an aquaporin-4 antibody test on a serum specimen to evaluate for neuromyelitis optica spectrum disorder (NMOSD). Blood is drawn in the outpatient clinic or phlebotomy lab and sent to the reference immunology laboratory. The laboratory performs a cell-based immunofluorescence assay (CBA) to detect IgG antibodies against aquaporin-4; results are reported to the ordering provider and documented in the electronic medical record. Typical sites of service include outpatient clinics, outpatient phlebotomy centers, hospital outpatient departments, and reference laboratories. The service type is a laboratory immunology test on serum for disease-specific autoantibody identification.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
26 | Professional component | When billing only the physician interpretation of the laboratory result (rare for standalone lab tests billed by performing lab) |
59 | Distinct procedural service | When this test is a distinct service from other performed tests and needs to be reported separately |
52 | Reduced services | If testing performed is limited or partially completed for clinical reasons |
53 | Discontinued procedure | If specimen collection or testing was started but discontinued |
78 | Unplanned return to the operating/procedure room by same physician following initial procedure | Data not typically applicable but included when procedural returns affect associated billing |
90 | Reference (outside) laboratory | When the performing laboratory is an independent reference lab and billed by another entity |
TC | Technical component | When billing only the technical component of the test (performed by the laboratory) |
QK | Qualified nonphysician laboratory director | When the service is furnished under a qualified nonphysician lab director |
QX | Service performed by an auxiliary personnel under CLIA-waived/directive | When auxiliary personnel performed the test under appropriate supervision |
QY | Attending physician waived or exempt laboratory director | When the attending physician meets CLIA qualifications for lab direction |
AS | Physician assistant, nurse practitioner, or clinical nurse specialist service | When an advanced practitioner orders or manages care related to the test and payer requires modifier for professional services |
| Taxonomy Code | Specialty | Notes |
|---|---|---|
| 207RG0100X | Neurology | Neurologists commonly order 86052 when evaluating optic neuritis, transverse myelitis, or suspected NMOSD |
| 207RE0101X | Neuroimmunology | Subspecialists in neuroimmunology frequently interpret results in complex demyelinating disease |
| 207L00000X | Allergy & Immunology | Immunologists may order or consult on autoimmune antibody testing and interpretation |
| 207K00000X | Pathology & Clinical Pathology | Pathologists or clinical laboratory directors oversee testing workflow and quality control |
| 364S00000X | Laboratory Medicine | Laboratory medicine specialists manage technical performance and reporting of CBA assays |
Related Diagnoses
| ICD-10 Code | Description | Clinical Relevance |
|---|---|---|
G36.0 | Neuromyelitis optica (Devic disease) | Primary diagnosis prompting 86052 testing to detect aquaporin-4 antibody |
G35 | Multiple sclerosis | Common alternative diagnosis; testing performed to differentiate MS from NMOSD |
H46.9 | Optic neuritis, unspecified | Clinical presentation leading to testing for AQP4 antibodies |
G37.3 | Other demyelinating diseases of central nervous system | Broader category for demyelinating presentations where AQP4 testing may be indicated |
G04.89 | Other encephalitis, myelitis and encephalomyelitis | When brainstem or spinal cord inflammation prompts autoimmune antibody evaluation |
Related CPT Codes
| CPT Code | Description | Relationship to This Procedure |
|---|---|---|
36415 | Collection of venous blood by venipuncture | Blood draw needed to obtain the serum specimen for 86052 |
86769 | Antibody; multiplex, quantitative or semiquantitative, multiple analytes (e.g., autoimmune panels) — (Note: use only when appropriate panels are performed) | Sometimes ordered alongside or as part of broader autoimmune serology panels when differential includes other autoantibodies |
86038 | Antibody; myelin oligodendrocyte glycoprotein (MOG) IgG, qualitative or semi-quantitative, each | Often ordered in parallel with 86052 to differentiate NMOSD related to AQP4 from MOG-associated disease |
88305 | Level IV surgical pathology, gross and microscopic examination | If biopsy specimens (rare) are obtained in differential diagnosis, pathology testing may be performed |
81162 | CYP2C19 (example pharmacogenomic) — (illustrative of molecular testing workflows) | Represents molecular testing workflows in the reference lab; not specific to 86052 but commonly present in complex laboratory portfolios |